Johannes Voortman

Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer

Jin‐Hyeok Hwang, Johannes Voortman, Elisa Giovannetti et al. · PLoS ONE · 2010 · 290 citations · Full text

Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors

Johannes Voortman, Jih‐Hsiang Lee, Jonathan Keith Killian et al. · Proceedings of the National Academy of Sciences · 2010 · 128 citations · Full text

Genetics, Pathology, Myc Family Members +18

MicroRNA Expression and Clinical Outcomes in Patients Treated with Adjuvant Chemotherapy after Complete Resection of Non–Small Cell Lung Carcinoma

Johannes Voortman, Akiteru Goto, Jean Mendiboure et al. · Cancer Research · 2010 · 125 citations · Full text

Surgical Oncology, Immunology, Adjuvant Chemotherapy +18

Phase I Study of DMOT4039A, an Antibody–Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

Colin D. Weekes, Laetitia E. Lamberts, Mitesh J. Borad et al. · Molecular Cancer Therapeutics · 2016 · 107 citations

Drug Targeting, Antibody-conjugated Mmae, Medicine +15

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment

Laetitia E. Lamberts, C. Willemien Menke‐van der Houven van Oordt, Eva J. ter Weele et al. · Clinical Cancer Research · 2015 · 96 citations